Dec. 15 Lead-Plaintiff Deadline Set in Baxter Securities Suit Over Novum IQ Pump

Plaintiffs allege the company hid systemic defects in the infusion pump that led to patient harm.

Overview

A federal securities class action has been filed for investors who bought Baxter stock between February 23, 2022 and July 30, 2025.
Investor notices from Bernstein Liebhard, Kirby McInerney, Faruqi & Faruqi, and Rosen Law highlight a December 15, 2025 deadline to seek lead-plaintiff status.
The complaints allege the Novum IQ Large Volume Pump suffered systemic defects causing underinfusion, overinfusion, and non-delivery, creating risks of serious injury or death.
Baxter warned customers in April and again on July 14, 2025, with the latter letter disclosing 79 serious-injury reports and two patient deaths linked to the device.
On July 31, 2025, Baxter paused shipments and installations of the Novum LVP with no restart date, and shares fell about 22.4% that day.